{"id":"raltegravir-tenofovir-emtricitabine","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Renal impairment (tenofovir-related)"},{"rate":null,"effect":"Bone density loss (tenofovir-related)"},{"rate":null,"effect":"Lactic acidosis (rare)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Raltegravir is an integrase strand transfer inhibitor (INSTI) that prevents HIV DNA from integrating into the host genome. Tenofovir is a nucleotide reverse transcriptase inhibitor and emtricitabine is a nucleoside reverse transcriptase inhibitor; together they block reverse transcription of viral RNA into DNA. This triple-mechanism approach provides potent suppression of HIV replication.","oneSentence":"This combination inhibits HIV replication by blocking integrase (raltegravir) and reverse transcriptase (tenofovir/emtricitabine) at different stages of the viral lifecycle.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:03:49.822Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-naïve and treatment-experienced patients"},{"name":"HIV-1 infection as part of combination antiretroviral therapy"}]},"trialDetails":[{"nctId":"NCT02016924","phase":"PHASE2, PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":133},{"nctId":"NCT06337032","phase":"PHASE4","title":"A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-27","conditions":"HIV-1-infection","enrollment":350},{"nctId":"NCT02302547","phase":"PHASE3","title":"Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2014-12","conditions":"HIV","enrollment":224},{"nctId":"NCT00042289","phase":"","title":"Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-06-09","conditions":"HIV Infections","enrollment":1578},{"nctId":"NCT06630299","phase":"PHASE3","title":"Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-10-08","conditions":"HIV-1-Infection","enrollment":600},{"nctId":"NCT05502341","phase":"PHASE2, PHASE3","title":"Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2022-08-16","conditions":"HIV-1-infection","enrollment":689},{"nctId":"NCT01234116","phase":"PHASE4","title":"Post-Exposure Prophylaxis in Health Care Workers","status":"COMPLETED","sponsor":"Henry Ford Health System","startDate":"2011-02","conditions":"Human Immunodeficiency Virus","enrollment":16},{"nctId":"NCT07080138","phase":"","title":"Research on the Psychological Status of Patients With HIV-1 Infection","status":"NOT_YET_RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-08-01","conditions":"HIV-1-infection, Anxiety Depression","enrollment":500},{"nctId":"NCT02285114","phase":"PHASE2, PHASE3","title":"Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2-Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-01-20","conditions":"HIV-1","enrollment":41},{"nctId":"NCT04442737","phase":"PHASE4","title":"A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2020-07-01","conditions":"HIV-1","enrollment":103},{"nctId":"NCT06338826","phase":"PHASE2","title":"Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses","status":"NOT_YET_RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2025-02-01","conditions":"HIV Infections, HBV Coinfection","enrollment":140},{"nctId":"NCT04012931","phase":"PHASE2","title":"A Study of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 Years) Who Are Virologically Suppressed","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-07-18","conditions":"HIV","enrollment":26},{"nctId":"NCT06037564","phase":"PHASE4","title":"B-free Multistage Trial","status":"ENROLLING_BY_INVITATION","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-11-13","conditions":"HIV, Drug Resistance, Drug Drug Interaction","enrollment":210},{"nctId":"NCT01712425","phase":"PHASE1","title":"Safety and Immunogenicity of ChAdV63.HIVconsv and MVA.HIVconsv Candidate HIV-1 Vaccines in Recently HIV-1 Infected Individuals","status":"COMPLETED","sponsor":"IrsiCaixa","startDate":"2012-10","conditions":"HIV","enrollment":48},{"nctId":"NCT03954327","phase":"PHASE2","title":"Combination Antiretroviral Therapy (cART) for PBC","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2021-03-01","conditions":"Primary Biliary Cholangitis","enrollment":37},{"nctId":"NCT00955968","phase":"PHASE4","title":"IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum Women","status":"COMPLETED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2010-01-01","conditions":"HIV Infection","enrollment":1653},{"nctId":"NCT05648201","phase":"PHASE4","title":"Study on PhArmacokinetics of First liNe Antiretrovirals in Healthy Breastfeeding Volunteers","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2023-03-01","conditions":"Hiv","enrollment":36},{"nctId":"NCT00594646","phase":"PHASE4","title":"HIV Non Occupational Post-Exposure Prophylaxis (PEP)","status":"COMPLETED","sponsor":"Fenway Community Health","startDate":"2008-02","conditions":"HIV Infections","enrollment":100},{"nctId":"NCT00660972","phase":"PHASE1","title":"Study of Viral Load Decay Rates in HIV Infected Participants Starting Treatment With Raltegravir (RAL) and Emtricitabine/Tenofovir Disoproxil Fumarate (TDF)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-05","conditions":"HIV Infections","enrollment":40},{"nctId":"NCT00852618","phase":"","title":"Intensive Viral Dynamics Substudy of A5248","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-05","conditions":"HIV Infections, Treatment Naive","enrollment":11},{"nctId":"NCT03631732","phase":"PHASE3","title":"Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-08-28","conditions":"HIV-1 Infection","enrollment":496},{"nctId":"NCT01147107","phase":"PHASE4","title":"Hepatic Safety of Raltegravir Versus Efavirenz as HIV Therapy for Patients With HIV and HCV Coinfection","status":"COMPLETED","sponsor":"University of Hawaii","startDate":"2014-02","conditions":"Hepatitis C, Chronic, HIV Infection","enrollment":80},{"nctId":"NCT01352715","phase":"PHASE3","title":"Study of Options for Second-Line Effective Combination Therapy (SELECT)","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2012-03-13","conditions":"HIV-1 Infection","enrollment":515},{"nctId":"NCT03394196","phase":"NA","title":"RESIST-2: 2nd-line ART for HIV-2 Infection","status":"TERMINATED","sponsor":"University of Washington","startDate":"2018-07-04","conditions":"HIV-2 Infection","enrollment":152},{"nctId":"NCT02616029","phase":"PHASE3","title":"Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-17","conditions":"HIV-1 Infection","enrollment":66},{"nctId":"NCT00752856","phase":"PHASE2","title":"Raltegravir + Lopinavir/Ritonavir Versus Efavirenz + Tenofovir + Emtricitabine in Treatment Naive Patients","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2008-08-26","conditions":"HIV Infections","enrollment":51},{"nctId":"NCT01025427","phase":"PHASE4","title":"HIV Persistence and Viral Reservoirs","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2009-12","conditions":"HIV, HIV Infections","enrollment":16},{"nctId":"NCT02121795","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-05-06","conditions":"HIV-1 Infection","enrollment":668},{"nctId":"NCT02616783","phase":"PHASE3","title":"Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-22","conditions":"HIV-1 Infection","enrollment":167},{"nctId":"NCT02995824","phase":"","title":"Effectiveness of Raltegravir-Based Antiretroviral Therapy in HIV-HCV Coinfected Liver Transplant Recipients","status":"COMPLETED","sponsor":"Hospital Clinic of Barcelona","startDate":"2002-01","conditions":"Liver Transplantation, HIV Infections, Antiretroviral Therapy","enrollment":271},{"nctId":"NCT00808002","phase":"PHASE3","title":"Efficacy of Treatment Intensification With Maraviroc on HIV-1 Viral Latency in Recently Infected Hiv-1 naïve Patients Starting Raltegravir Plus Tenofovir/Emtricitabine","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2009-02","conditions":"HIV Infections","enrollment":30},{"nctId":"NCT01335620","phase":"PHASE4","title":"The Safety, Pharmacokinetic Profile and Efficacy of Raltegravir in HIV-infected Patients at Least 60 Years of Age","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2011-04","conditions":"HIV","enrollment":19},{"nctId":"NCT01293123","phase":"NA","title":"Raltegravir Cerebrospinal Fluid Pharmacodynamic Study in HIV-Infected Individuals","status":"TERMINATED","sponsor":"University of California, San Diego","startDate":"2011-12","conditions":"HIV","enrollment":2},{"nctId":"NCT02469246","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-06-29","conditions":"HIV-1 Infection","enrollment":567},{"nctId":"NCT02150993","phase":"PHASE2, PHASE3","title":"First-Line Treatment for HIV-2","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2016-01-26","conditions":"HIV-2 Infection","enrollment":210},{"nctId":"NCT02116660","phase":"PHASE2","title":"Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-09-03","conditions":"HIV Infections","enrollment":11},{"nctId":"NCT01641367","phase":"PHASE4","title":"A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2013-02-22","conditions":"HIV-1 Infection","enrollment":545},{"nctId":"NCT03842488","phase":"PHASE4","title":"Raltegravir One Thousand Two Hundred vs Darunavir-cb in Immnunosupressed Patients: ROTDIP Study","status":"UNKNOWN","sponsor":"Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud","startDate":"2019-04","conditions":"HIV Infections","enrollment":75},{"nctId":"NCT02131233","phase":"PHASE3","title":"Evaluation of the Safety and Efficacy of Reformulated Raltegravir (MK-0518) 1200 mg Once Daily in Combination With TRUVADA™ in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-Naive Participants (MK-0518-292)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-05-23","conditions":"HIV Infection","enrollment":802},{"nctId":"NCT02218320","phase":"","title":"Comparison of Virologic and Immunologic Responses to Raltegravir and Dolutegravir in the Gastrointestinal Tract of HIV-Positive Adults","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2014-10","conditions":"Human Immunodeficiency Virus","enrollment":20},{"nctId":"NCT02605954","phase":"PHASE3","title":"Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-18","conditions":"HIV-1 Infection","enrollment":275},{"nctId":"NCT01902186","phase":"PHASE4","title":"Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir","status":"TERMINATED","sponsor":"Giovanni Di Perri","startDate":"2014-09","conditions":"HIV Infection, Osteopenia","enrollment":4},{"nctId":"NCT01227824","phase":"PHASE3","title":"A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2010-10-19","conditions":"Infection, Human Immunodeficiency Virus I","enrollment":828},{"nctId":"NCT00632970","phase":"PHASE4","title":"Raltegravir vs. Lopinavir/Ritonavir, Both in Combination With Truvada, in HIV+ Treatment Naive Individuals","status":"TERMINATED","sponsor":"George Washington University","startDate":"2008-02","conditions":"HIV Infections","enrollment":6},{"nctId":"NCT01605890","phase":"PHASE2","title":"Trial Evaluating a First Line Combination Therapy With Raltegravir, Emtricitabine and Tenofovir in HIV-2 Infected Patients","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2012-07","conditions":"HIV-2 Infection","enrollment":30},{"nctId":"NCT01450189","phase":"NA","title":"A Key Link for Transmission Prevention","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2011-10","conditions":"HIV","enrollment":46},{"nctId":"NCT03256422","phase":"PHASE3","title":"Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients","status":"UNKNOWN","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2017-09-07","conditions":"HIV Infections","enrollment":640},{"nctId":"NCT00641641","phase":"NA","title":"The Effect of Raltegravir on HIV Decay During Primary and Chronic Infection","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2008-03","conditions":"HIV Infection","enrollment":16},{"nctId":"NCT00931801","phase":"PHASE4","title":"BATAR: Individuals Currently Taking Boosted Atazanavir as Part of an HIV Treatment Regimen Will be Evaluated to See if Substituting Raltegravir for Nucleoside Transcriptase Inhibitors Will be Safe and Well Tolerated.","status":"COMPLETED","sponsor":"Community Research Initiative of New England","startDate":"2009-12","conditions":"HIV","enrollment":43},{"nctId":"NCT02449733","phase":"NA","title":"Comprehensive HIV Prevention Package for MSM in Port Elizabeth","status":"COMPLETED","sponsor":"Emory University","startDate":"2015-05","conditions":"HIV","enrollment":101},{"nctId":"NCT02351908","phase":"PHASE4","title":"Renal Integrase Study","status":"COMPLETED","sponsor":"St Stephens Aids Trust","startDate":"2015-03","conditions":"HIV","enrollment":60},{"nctId":"NCT01173510","phase":"PHASE4","title":"A Pilot Study to Determine if Raltegravir Eradicates HIV From Peripheral Blood Mononuclear Cells","status":"WITHDRAWN","sponsor":"Community Research Initiative of New England","startDate":"2010-08-23","conditions":"HIV Infections, Acquired Immune Deficiency Syndrome","enrollment":""},{"nctId":"NCT01456962","phase":"","title":"Influence of Antiretroviral Regimen on Immune Reconstitution in the Female Genital Tract","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2011-10","conditions":"Women's Health, HIV Infection, Genital Diseases, Female","enrollment":36},{"nctId":"NCT00369941","phase":"PHASE3","title":"A Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus Efavirenz in Treatment Naive HIV-Infected Patients, Each in Combination With TRUVADA (0518-021 EXT)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-08","conditions":"HIV Infections","enrollment":566},{"nctId":"NCT00745823","phase":"PHASE3","title":"A Study to Determine the Safety and Efficacy of Once Daily Raltegravir Compared to Twice Daily Raltegravir (MK-0518-071)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-09","conditions":"HIV","enrollment":775},{"nctId":"NCT00667433","phase":"PHASE1","title":"Raltegravir as Early Therapy in African-Americans Living With HIV Study","status":"COMPLETED","sponsor":"David A Wohl, MD","startDate":"2008-06","conditions":"HIV Infections","enrollment":38},{"nctId":"NCT01114425","phase":"PHASE3","title":"Safety Study of Isentress® + Truvada® in Post-exposure Treatment of HIV Infection","status":"COMPLETED","sponsor":"Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux","startDate":"2010-11-01","conditions":"HIV Infections","enrollment":149},{"nctId":"NCT01829802","phase":"PHASE4","title":"RAL+ATV/r in Comparison With TDF/FTC (or 3TC) +ATV/r in HIV Infected Patients","status":"UNKNOWN","sponsor":"Pedro Cahn","startDate":"2014-05","conditions":"Chronic Infection With HIV","enrollment":50},{"nctId":"NCT01285050","phase":"PHASE4","title":"Interferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV Meds","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2011-01","conditions":"HIV Infection, Hepatitis C","enrollment":20},{"nctId":"NCT00734344","phase":"NA","title":"Pilot Study of Raltegravir/Truvada Versus Efavirenz/Truvada for Adults With Acute IV-1 Infection","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2008-09","conditions":"Acute HIV Infection","enrollment":18},{"nctId":"NCT00708162","phase":"PHASE3","title":"Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2008-07","conditions":"HIV Infection","enrollment":724},{"nctId":"NCT01154673","phase":"PHASE2, PHASE3","title":"Effects of Intensive cART During Acute/Early HIV Infection","status":"COMPLETED","sponsor":"University of Toronto","startDate":"2011-11","conditions":"Acute HIV Infection","enrollment":32},{"nctId":"NCT01214759","phase":"PHASE4","title":"Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP)","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2011-05","conditions":"HIV","enrollment":103},{"nctId":"NCT00851799","phase":"","title":"Impact of Antiretroviral Therapy on Metabolic, Skeletal, and Cardiovascular Parameters","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2009-06","conditions":"HIV Infection","enrollment":334},{"nctId":"NCT01291459","phase":"PHASE2","title":"Pilot Study of Maraviroc/Raltegravir for Naive HIV-1 Patients","status":"UNKNOWN","sponsor":"Association Pour la Recherche en Infectiologie","startDate":"2011-09","conditions":"HIV","enrollment":40},{"nctId":"NCT01908660","phase":"","title":"Hepatic Safety of Currently Used Antiretroviral Regimens in Patients With Chronic Hepatitis Under Real Life Conditions","status":"COMPLETED","sponsor":"Valme University Hospital","startDate":"2007-01","conditions":"Human Immunodeficiency Virus, Hepatitis B, Chronic, Hepatitis C, Chronic","enrollment":192},{"nctId":"NCT00654147","phase":"PHASE2","title":"Raltegravir + Lopinavir/Ritonavir or Emtricitabine/Tenofovir for HIV Treatment Naive Subjects","status":"COMPLETED","sponsor":"Margaret A. Fischl, M.D.","startDate":"2008-04","conditions":"HIV Infections","enrollment":44},{"nctId":"NCT01225705","phase":"PHASE4","title":"Safety Study of Raltegravir in HIV/HCV Co-infected Patients","status":"WITHDRAWN","sponsor":"University Hospital, Bonn","startDate":"2010-10","conditions":"HIV, Hepatitis C","enrollment":""},{"nctId":"NCT00863668","phase":"NA","title":"Raltegravir Activity In Lymphoid Tissues","status":"WITHDRAWN","sponsor":"University of Minnesota","startDate":"2009-03","conditions":"HIV Infection, HIV Infections","enrollment":""},{"nctId":"NCT00984152","phase":"PHASE3","title":"Trial of TDF/FTC + Raltegravir Versus TDF/FTC + Efavirenz in HIV-1-Infected Women","status":"WITHDRAWN","sponsor":"Rush University Medical Center","startDate":"2011-06","conditions":"HIV-1 Infections","enrollment":""},{"nctId":"NCT01576731","phase":"PHASE4","title":"Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: Tenofovir + Emtricitabine + Lopinavir/Ritonavir Versus Tenofovir + Emtricitabine + Raltegravir (RAL-PEP)","status":"COMPLETED","sponsor":"Hospital Clinic of Barcelona","startDate":"2012-07","conditions":"HIV Infection","enrollment":240},{"nctId":"NCT01294761","phase":"NA","title":"Comparing Continuing Tenofovir, Emtricitabine (or Lamivudine) Plus Lopinavir and Switching to Raltegravir Plus Darunavir","status":"COMPLETED","sponsor":"National Center for Global Health and Medicine, Japan","startDate":"2011-02","conditions":"HIV Infections","enrollment":59},{"nctId":"NCT00525733","phase":"NA","title":"Standard Antiretroviral v. Multi-class Therapy in Acutely HIV-1 Infected Antiretroviral-Naïve Subjects (ADARC 2007-01)","status":"COMPLETED","sponsor":"Rockefeller University","startDate":"2007-10","conditions":"HIV Infections","enrollment":40},{"nctId":"NCT01332227","phase":"PHASE4","title":"Atazanavir/Ritonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1-Infected Patients","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-10","conditions":"HIV, Combination Therapy","enrollment":132},{"nctId":"NCT00958100","phase":"PHASE2","title":"Raltegravir Switch for Toxicity or Adverse Events","status":"COMPLETED","sponsor":"Catholic University of the Sacred Heart","startDate":"2009-08","conditions":"HIV/AIDS, Antiretroviral Therapy, HIV Infections","enrollment":40},{"nctId":"NCT01533259","phase":"PHASE3","title":"Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2012-01","conditions":"Acquired Immunodeficiency Syndrome, HIV Infections","enrollment":48},{"nctId":"NCT01258439","phase":"PHASE4","title":"Post-prandial Lipid Effects of Raltegravir (RAL) vs Ritonavir -Boosted Darunavir (DRV-r) in Anti-retroviral Therapy (ART)- Naive Adults or Adults Recommencing ART.","status":"COMPLETED","sponsor":"St Vincent's Hospital, Sydney","startDate":"2010-11","conditions":"HIV, Cardiovascular Disease","enrollment":25},{"nctId":"NCT00762892","phase":"PHASE4","title":"Raltegravir vs. Atazanavir in Combination With Truvada® for the Treatment of Antiretroviral naïve HIV Infected Patients","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2009-01","conditions":"HIV Infections","enrollment":33},{"nctId":"NCT01195467","phase":"PHASE3","title":"Atripla to Raltegravir Switch Study for CNS Toxicity","status":"COMPLETED","sponsor":"St Stephens Aids Trust","startDate":"2010-10","conditions":"HIV Infection","enrollment":40},{"nctId":"NCT01565889","phase":"PHASE1, PHASE2","title":"Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2012-03","conditions":"Hepatitis C, HIV","enrollment":52},{"nctId":"NCT00677300","phase":"PHASE4","title":"Raltegravir And Darunavir Antiretroviral in Antiretroviral Naive Patients","status":"COMPLETED","sponsor":"Dallas VA Medical Center","startDate":"2009-01","conditions":"HIV Infections","enrollment":85},{"nctId":"NCT00811954","phase":"PHASE3","title":"Comparative Study of Three NNRTI-Sparing HAART Regimens","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2009-05","conditions":"HIV Infection","enrollment":1814},{"nctId":"NCT00624195","phase":"PHASE2, PHASE3","title":"Clinical Trial of CNS-targeted HAART (CIT2)","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2007-03","conditions":"HIV Infections","enrollment":59},{"nctId":"NCT01087840","phase":"PHASE4","title":"Raltegravir Use as Nonoccupational Postexposure Prophylaxis (NPEP) in Men Who Have Sex With Men","status":"COMPLETED","sponsor":"Andrew Carr","startDate":"2010-07","conditions":"HIV Prevention, HIV Infections","enrollment":120},{"nctId":"NCT01033760","phase":"PHASE3","title":"Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM)","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2010-04","conditions":"HIV-1 Infections","enrollment":90},{"nctId":"NCT01270802","phase":"PHASE4","title":"Effects of Switching Efavirenz to Raltegravir on Vascular Function and Bone Markers in HIV-infected Patients","status":"COMPLETED","sponsor":"Indiana University","startDate":"2011-04","conditions":"HIV","enrollment":30},{"nctId":"NCT01066962","phase":"PHASE3","title":"Study of Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir in HIV-infected Antiretroviral naïve Subjects","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2010-08","conditions":"HIV Infections","enrollment":800},{"nctId":"NCT01330199","phase":"PHASE1","title":"Pharmacokinetics of Tenofovir, Emtricitabine, Maraviroc, and Raltegravir in Cervical, Vaginal, and Rectal Tissues and Secretions","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2012-02","conditions":"Healthy Adult Females","enrollment":49},{"nctId":"NCT01697046","phase":"PHASE3","title":"A Pilot Study on Raltegravir, Tenofovir and Emtricitabine for Peri-exposure Prophylaxis for HIV Infection","status":"UNKNOWN","sponsor":"Projeto Praça Onze","startDate":"2012-11","conditions":"Infection, HIV","enrollment":65},{"nctId":"NCT00666055","phase":"","title":"Sex, Aging and Antiretroviral Pharmacokinetics","status":"COMPLETED","sponsor":"Kristine Patterson, MD","startDate":"2008-03","conditions":"HIV Infections","enrollment":11},{"nctId":"NCT00768989","phase":"PHASE2","title":"Phase IIB Pilot of Atazanavir + Raltegravir","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2008-11","conditions":"HIV","enrollment":167},{"nctId":"NCT00711009","phase":"PHASE3","title":"Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL)","status":"COMPLETED","sponsor":"Abbott","startDate":"2008-07","conditions":"Human Immunodeficiency Virus Infection","enrollment":206},{"nctId":"NCT01105611","phase":"PHASE4","title":"Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug Users","status":"UNKNOWN","sponsor":"St. James's Hospital, Ireland","startDate":"2010-08","conditions":"HIV Infections, Hepatitis C","enrollment":40},{"nctId":"NCT01343225","phase":"PHASE4","title":"Effect of a Non-tenofovir, Non-efavirenz-based HIV Regimen on Bone Density and Vitamin D Levels in African-American Patients With HIV Infection","status":"UNKNOWN","sponsor":"East Carolina University","startDate":"2011-05","conditions":"HIV","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Raltegravir, tenofovir/emtricitabine","genericName":"Raltegravir, tenofovir/emtricitabine","companyName":"University of California, San Francisco","companyId":"university-of-california-san-francisco","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination inhibits HIV replication by blocking integrase (raltegravir) and reverse transcriptase (tenofovir/emtricitabine) at different stages of the viral lifecycle. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients, HIV-1 infection as part of combination antiretroviral therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}